• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

FDA Approves First Treatment for Eosinophilic Esophagitis

by Amy E. Hamaker • June 27, 2022

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

In May, the U.S. Food and Drug Administration approved dupilumab (Dupixent) as a treatment for eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. Dupilumab, originally approved by the FDA in 2017, is a monoclonal antibody that acts to inhibit part of the inflammatory pathway.

You Might Also Like

  • Eosinophilic Esophagitis, CRS Show Associations as Comorbid Conditions
  • Otolaryngologists Well-Positioned for Diagnosis, Treatment of Pediatric Patients with Eosinophilic Esophagitis
  • Eosinophilic Esophagitis: Serious But Misunderstood
  • How the U.S. FDA Approves Medical Devices

Dupilumab’s efficacy and safety in EoE was studied in a randomized, double-blind, parallel-group, multicenter, placebo-controlled trial that included two 24-week treatment periods (Part A and Part B) that were conducted independently in separate groups of patients. Patients in both parts received either a placebo or 300 milligrams of dupilumab every week. The two primary measurements of efficacy were the proportion of patients who achieved a certain level of reduced eosinophils in the esophagus at week 24 (determined by assessing esophageal tissue under a microscope) and change in the patient-reported Dysphagia Symptom Questionnaire (DSQ) score from baseline to week 24.

Sixty percent of the 42 Part A patients who received dupilumab achieved the predetermined level of reduced eosinophils in the esophagus compared to 5% of the 39 patients who received a placebo. Part A patients in who received dupilumab experienced an average improvement of 22 points in their DSQ score compared to 10 points in patients who received a placebo. In Part B, 59% of the 80 patients who received dupilumab achieved the predetermined level of reduced eosinophils in the esophagus compared to 6% of the 79 patients who received a placebo; Part B patients who received dupilumab had an average 24-point improvement in their DSQ score compared to 14 points for placebo patients.

Filed Under: Laryngology, Online Exclusives, Practice Focus Tagged With: dupilumab, eosinophilic esophagitis, patient care

You Might Also Like:

  • Eosinophilic Esophagitis, CRS Show Associations as Comorbid Conditions
  • Otolaryngologists Well-Positioned for Diagnosis, Treatment of Pediatric Patients with Eosinophilic Esophagitis
  • Eosinophilic Esophagitis: Serious But Misunderstood
  • How the U.S. FDA Approves Medical Devices

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Would you choose a concierge physician as your PCP?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • 22 Symptoms Common to Patients with Superior Canal Dehiscence Syndrome

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Keeping Watch for Skin Cancers on the Head and Neck

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Excitement Around Gene Therapy for Hearing Restoration
    • “Small” Acts of Kindness
    • How To: Endoscopic Total Maxillectomy Without Facial Skin Incision
    • Science Communities Must Speak Out When Policies Threaten Health and Safety
    • Observation Most Cost-Effective in Addressing AECRS in Absence of Bacterial Infection

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939